【24h】

Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors

机译:针对HIV-1蛋白酶抑制剂的耐药途径的贝叶斯网络分析

获取原文
获取原文并翻译 | 示例
           

摘要

Interpretation of Human Immunodeficiency Virus 1 (HIV-1) genotypic drug resistance is still a major challenge in the follow-up of antiviral therapy in infected patients. Because of the high degree of HIV-1 natural variation, complex interactions and stochastic behaviour of evolution, the role of resistance mutations is in many cases not well understood. Using Bayesian network learning of HIV-1 sequence data from diverse subtypes (A, B, C, F and G), we could determine the specific role of many resistance mutations against the protease inhibitors (PIs) nelfinavir (NFV), indinavir (IDV), and saquinavir (SQV). Such networks visualize relationships between treatment, selection of resistance mutations and presence of polymorphisms in a graphical way. The analysis identified 30N, 88S, and 90M for nelfinavir, 90M for saquinavir, and 82A/T and 46I/L for indinavir as most probable major resistance mutations. Moreover we found striking similarities for the role of many mutations against all of these drugs. For example, for all three inhibitors, we found that the novel mutation 89I was minor and associated with mutations at positions 90 and 71. Bayesian network learning provides an autonomous method to gain insight in the role of resistance mutations and the influence of HIV-1 natural variation. We successfully applied the method to three protease inhibitors. The analysis shows differences with current knowledge especially concerning resistance development in several non-B subtypes.
机译:解释人类免疫缺陷病毒1(HIV-1)基因型耐药性仍是感染患者抗病毒治疗后续行动中的主要挑战。由于高度的HIV-1自然变异,复杂的相互作用和进化的随机行为,在许多情况下,抗药性突变的作用尚不十分清楚。使用来自不同亚型(A,B,C,F和G)的HIV-1序列数据的贝叶斯网络学习,我们可以确定针对蛋白酶抑制剂(PIs)的奈芬那韦(NFV),茚地那韦(IDV)的许多抗性突变的特定作用)和saquinavir(SQV)。这样的网络以图形化方式可视化了治疗,耐药性突变选择和多态性存在之间的关系。该分析确定奈芬那韦为30N,88S和90M,沙奎那韦为90M,茚地那韦为82A / T和46I / L是最可能的主要耐药突变。此外,我们发现针对所有这些药物的许多突变的作用具有惊人的相似性。例如,对于所有三种抑制剂,我们发现新颖的突变89I较小,并且与90和71位的突变相关。贝叶斯网络学习提供了一种自主方法来深入了解耐药突变的作用和HIV-1的影响自然变化。我们成功地将该方法应用于三种蛋白酶抑制剂。该分析显示了与当前知识的差异,特别是在几种非B亚型的抗性发展方面。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号